Carcinoma of the Uterine Cervix: Twice- versus Once-weekly High-Dose-Rate Brachytherapy

Hama, Yukihiro; Uematsu, Minoru; Nagata, Ichiro; Shioda, Akira; Suda, Atsushi; Sakurai, Yoshinori; Kono, Masashi; Tamura, Taiji; Kusano, Shoichi

doi:10.1148/radiology.219.1.r01ap08207

Cited by 13 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,21 Lack of standardization of the conversion used complicates dose comparison between studies. The 1999 ABS survey on brachytherapy practice in the United States showed that physicians administering HDR gave an average dose of 48-50 Gy to the pelvis in EBRT with an additional 30 Gy in five fractions of HDR brachytherapy.…”

Section: Dose and Fractionationmentioning

confidence: 99%

See 1 more Smart Citation

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Stewart¹,

Viswanathan²

2006

Cancer

View full text Add to dashboard Cite

The use of brachytherapy in the treatment of cervical cancer has increased worldwide since its initial introduction over 100 years ago. However, certain aspects of the use of high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy continue to be controversial, particularly the role of HDR in FIGO Stage III cervical cancer and the use of HDR with concurrent chemotherapy. This study represents a systematic literature review of prospective and retrospective series of patients with cervical carcinoma treated with external-beam radiation

show abstract

Section: Dose and Fractionationmentioning

confidence: 99%

“…22 With HDR the probability of late damage increases as the dose increases and the number of fractions decreases. 20,21 This probability is also related to the percentage of dose received by normal tissue. If the normal tissue received 100% of the dose, 30 fractions would be needed for equivalent late complications with LDR.…”

Section: Dose and Fractionationmentioning

confidence: 99%

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Stewart¹,

Viswanathan²

2006

Cancer

View full text Add to dashboard Cite

show abstract

“…Although it should be mandatory not to give EBRT on the day of HDR-BT [1]. Also, it was reported that patients treated using a twice-weekly HDR BT schedule had better local recurrence-free survival than did patients treated using once-weekly BT when the implants were inserted after EBRT completion (20) . The recommended duration from the American Brachytherapy Society is to keep the total treatment duration to 8 weeks (21) .…”

Section: Discussionmentioning

confidence: 99%

Overall Treatment Time Assessment of Locally Advanced Cervix Cancer

Abbassi¹,

Echchikhi²,

Touil³

et al. 2017

IAM

View full text Add to dashboard Cite

Background: Overall treatment time is an important factor in the outcome of cervix cancer treatment. However, in daily clinical practice, unplanned treatment interruptions are inevitable for many reasons. We performed a prospective study to assess the overall treatment time for patients treated in our department and identify the causes of treatment prolongation. Material and methods: Between first January and 30 April 2016, a group of patients with locally advanced cervix cancer was interviewed at the end of treatment. Data was collected using a questionnaire containing important study parameters. Results: 100 patients were interviewed. The mean age of women was 55,08 ± 12,43 years. Seventy-five patients (75%) were illiterate. Ninety-six patients (96%) has low socio-economic level. Ninety patients (90%) has squamous cell carcinoma. The stage IIIB represented the majority of cases (90%). All patients were treated with concurrent chemoradiation except one patient. Pelvic radiation at the dose of 46 Gy was performed for all patients. The median time to complete pelvis RT was 37 days (34-42 days). Only seventy-seven patients (77%) were treated by BT. A median time of the first brachytherapy insertion was 13,50 days (0-20 days). The median of OTT was 71 days (64-78 days). This prolongation was mainly due to the delay of the first brachytherapy insertion. In the univariate and multivariate analysis, 2 factors were associated with longer overall treatment time: age (p=0,006) and stage (p=0,001). Conclusion: In our country, cervical cancer outcomes are still poor. To improve the prognosis, overall treatment time should be given in timely manner (8weeks).

show abstract

“…Yukihiro Hama et al (1991) [29]have been studied effectiveness and safety of twice-weekly HDRICBT in cervical carcinoma, showed that twice-weekly regimen substantially improve local control (p<.01) and reduced moderate and severe complications (p <.01). However, despite improvements in local control and severe complications, overall survival was not significantly improved, because 93% of patients who developed localregional recurrences had also distant metastasis, and most of death occurs due to metastasis and multiorgans failure.…”

Section: Discussionmentioning

confidence: 99%

“The effect of treatment prolongation in treatment of cervical cancer patient” –treated patients at rural center in India”

Chandel¹

2013

IOSR-JDMS

View full text Add to dashboard Cite

show abstract

Carcinoma of the Uterine Cervix: Twice- versus Once-weekly High-Dose-Rate Brachytherapy

Abstract: The twice-weekly HDR regimen may improve the local control rate with fewer complications.

Cited by 13 publications

References 23 publications

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Current controversies in high‐dose‐rate versus low‐dose‐rate brachytherapy for cervical cancer

Overall Treatment Time Assessment of Locally Advanced Cervix Cancer

“The effect of treatment prolongation in treatment of cervical cancer patient” –treated patients at rural center in India”

Contact Info

Product

Resources

About